
AbbVie acquires Apogee Therapeutics for 9.5 billion to strengthen its immunology business
The American pharmaceutical group AbbVie has announced the purchase of the biotechnology company Apogee Therapeutics for approximately 10.9 billion dollars (around 9.5 billion euros). With this operation, the company aims to strengthen and expand its catalog of treatments in the field of immunology.The agreement contemplates the acquisition of 100% of...`>